Developer docs
API playgroundTry for free, no card

Search company profiles

Diality

Full company profile

uuid0000ozk

Namestring
Diality
Legal namestring
Diality, Inc.
Websiteurl
diality.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Diality is a privately held medical device company headquartered in Irvine, California, developing the Moda-flx Hemodialysis System for the treatment of acute and chronic kidney disease. The platform integrates reverse osmosis water filtration with variable dialysate and blood flow rate capabilities, supporting treatment modalities ranging from sustained low-efficiency dialysis (SLED) through thrice-weekly in-center hemodialysis, packaged in a mobile form factor on a custom cart. A cloud-based data portal accompanies the device, enabling centralized treatment data capture and remote visibility across care settings.

The intended commercial model is B2B direct enterprise sales of capital equipment paired with recurring consumable cartridge revenue, targeting acute care hospitals, skilled nursing facilities, and chronic care clinics, with home dialysis pursued as a follow-on indication through the PRESCRIBE clinical trial. The Moda-flx system received FDA 510(k) clearance in August 2024 for professional care settings, with a limited market release targeted for 2027. Diality has raised approximately $82.5M across five funding rounds between 2018 and 2023, and operates with 11-50 employees under leadership combining clinical nephrology expertise (founder and CEO Osman Khawar, MD) with veteran dialysis industry operators on both the executive team and board.

The company remains pre-revenue as of the available data, with current activities centered on clinical trial execution, manufacturing partnership operations (Paramit), and pre-commercial organizational buildout including the recent CFO appointment.

Short descriptiontext

Diality is a medical device company developing the Moda-flx Hemodialysis System, a mobile, connected hemodialysis platform with integrated reverse osmosis water filtration, targeting acute care hospitals, skilled nursing facilities, chronic care clinics, and ultimately home dialysis patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hemodialysis equipment, dialysis machines, medical devices, kidney care, water filtration systems
Industry3 codes
PRIMARYHLAHAKAA
Hemodialysis Machines & Systems
SECONDARYHLAHAKAF
Continuous Renal Replacement Therapy (CRRT) & Acute Dialysis Systems
SECONDARYHLALAFAC
Kidney & Dialysis Remote Care (CKD/ESRD monitoring, home dialysis support)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code1 code
  • Kidney Dialysis Centers621492
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Hemodialysis Systems / Dialysis Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Hemodialysis System Sales
TypeHardware Sales
Description

Diality generates revenue through the sale of its Moda-flx Hemodialysis System to healthcare facilities including hospitals, skilled nursing facilities, and clinics. The system includes capital equipment and single-use consumables (cartridges).

diality.com
2Consumables and Accessories
TypeSubscription Recurring
Description

Ongoing revenue from single-use cartridges required for each dialysis treatment session, providing a recurring consumables revenue stream.

diality.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Moda-flx
Description

The Moda-flx Hemodialysis System is a hemodialysis platform designed to empower healthcare professionals to choose personalized hemodialysis prescriptions for patients' needs, featuring a fully integrated reverse osmosis water filtration system and an intuitive user interface designed to be easy to learn and use.

diality.com
Core offering1 text field

Diality develops and manufactures the Moda-flx Hemodialysis System, a mobile, connected hemodialysis platform with integrated reverse osmosis water filtration that enables on-demand dialysate generation from tap water. The system supports a broad range of prescriptions (IHD, SLED/SLEDD, PIRRT, and 3X weekly in-center treatments) and is intended for use in acute care hospitals, post-acute care facilities, chronic care settings, and (under IDE clinical trial) home use. Revenue is generated through capital equipment sales and recurring single-use consumable cartridges to healthcare facilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Training time reduced to under 4 hours for new users
+2 more records
Product overview1 text field

Diality offers a single unified product: the Moda-flx Hemodialysis System. This hemodialysis platform is designed to empower healthcare professionals to choose personalized prescriptions for kidney disease patients across various care settings. The system features fully integrated reverse osmosis water filtration, prescription flexibility supporting treatments ranging from SLED to 3X weekly in-center treatments, and a cloud-based portal for data-driven clinical decisions.

Product and service1 record
1Moda-flx Hemodialysis System
CategoryHemodialysis capital equipment and platform
Description

A mobile, connected hemodialysis platform for acute care hospitals, post-acute care facilities, chronic care settings, and (under IDE) home use, featuring integrated reverse osmosis water filtration, variable dialysate and blood flow rates, a cloud-based physician data portal, and an intuitive user interface enabling sub-4-hour training.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-11
Description

Diality partnered with aQua Research Institute for the PRESCRIBE Diality Home Hemodialysis Clinical Trial. The institute serves as a clinical trial site for evaluating home use of the Moda-flx system by ESRD patients on stable dialysis regimens.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-11
Description

aQua Dialysis in Houston, Texas is a clinical trial site partner for the PRESCRIBE Diality Home Hemodialysis Clinical Trial, treating the first patient in the home use evaluation of the Moda-flx system.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-07
Description

First-ever patient treatment with the Moda-flx Hemodialysis System was completed in collaboration with North America Research Institute at Ontario-Holt Dialysis Center in Ontario, California, marking the initial clinical use of the system.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-08-14
Description

Diality joined Kidney Care Partners, the nation's leading kidney care multi-stakeholder coalition representing patient advocates, physician organizations, health professional groups, dialysis providers, researchers, and manufacturers. Membership provides networking and advocacy opportunities in the kidney care ecosystem.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-28
Description

Diality partnered with Paramit Corporation for the manufacture of its versatile hemodialysis system. The partnership was established to accelerate production and bring the system closer to market.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Outset Medical's Tablo Hemodialysis System is the most direct competitor to Diality's Moda-flx: a next-generation, integrated water-purification, mobile hemodialysis platform marketed across acute, in-center, and home settings. Both target the same workflow-simplification and infrastructure-reduction thesis.

TypeDirect peer
Description

Quanta's SC+ is a compact, portable hemodialysis system designed for flexibility across care settings including home use. Like Diality, Quanta targets the same underserved segments (SNF, home) with a simplified, mobile platform that challenges legacy in-center systems.

TypeBroad incumbent
Description

Fresenius is the global leader in dialysis products and services, having acquired NxStage Medical (home hemodialysis). It sells a broad portfolio of hemodialysis machines, dialyzers, and operates thousands of dialysis centers worldwide, directly competing with Diality on both device sales and downstream service economics.

TypeBroad incumbent
Description

Baxter's kidney care business (recently separated as Vantive) is a long-standing incumbent in hemodialysis systems, PD systems, and dialyzers. It serves the same hospital, in-center, and home dialysis customers as Diality and has the scale, GPO contracts, and installed base to defend share aggressively.

TypeDirect peer
Description

NxStage pioneered home hemodialysis with the System One and was acquired by Fresenius. Its home-hemodialysis-first design philosophy and adoption among home patients overlap directly with Diality's PRESCRIBE home trial strategy.

6Asahi Kasei Medical
TypeBroad incumbent
Description

Asahi Kasei is a leading global manufacturer of dialyzers and a broader renal-care portfolio. While not a direct machine-systems competitor, it is a major incumbent supplier to dialysis providers and serves overlapping nephrology customers.

7Nipro Corporation
TypeBroad incumbent
Description

Nipro is a significant manufacturer of dialyzers, dialysis machines, and related renal-care products, with growing presence in the U.S. dialysis market. It competes with Diality for hospital and clinic dialysis equipment spend.

TypeOthers
Description

Mar Cor is a leading provider of water purification systems for dialysis clinics — the very infrastructure Diality's integrated RO system is designed to displace. It is an adjacent/ecosystem competitor whose installed water rooms represent both an opportunity (retrofit) and a barrier (switching cost) for Diality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Diality

Hemodialysis Systems / Dialysis Medical Devicesdiality.com

Diality is a medical device company developing the Moda-flx Hemodialysis System, a mobile, connected hemodialysis platform with integrated reverse osmosis water filtration, targeting acute care hospitals, skilled nursing facilities, chronic care clinics, and ultimately home dialysis patients.

What Diality does

Diality is a privately held medical device company headquartered in Irvine, California, developing the Moda-flx Hemodialysis System for the treatment of acute and chronic kidney disease. The platform integrates reverse osmosis water filtration with variable dialysate and blood flow rate capabilities, supporting treatment modalities ranging from sustained low-efficiency dialysis (SLED) through thrice-weekly in-center hemodialysis, packaged in a mobile form factor on a custom cart. A cloud-based data portal accompanies the device, enabling centralized treatment data capture and remote visibility across care settings.

The intended commercial model is B2B direct enterprise sales of capital equipment paired with recurring consumable cartridge revenue, targeting acute care hospitals, skilled nursing facilities, and chronic care clinics, with home dialysis pursued as a follow-on indication through the PRESCRIBE clinical trial. The Moda-flx system received FDA 510(k) clearance in August 2024 for professional care settings, with a limited market release targeted for 2027. Diality has raised approximately $82.5M across five funding rounds between 2018 and 2023, and operates with 11-50 employees under leadership combining clinical nephrology expertise (founder and CEO Osman Khawar, MD) with veteran dialysis industry operators on both the executive team and board.

The company remains pre-revenue as of the available data, with current activities centered on clinical trial execution, manufacturing partnership operations (Paramit), and pre-commercial organizational buildout including the recent CFO appointment.

Diality firmographics

Firmographics
Name
Diality
Legal name
Diality, Inc.
Website
https://diality.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
Diality is a medical device company developing the Moda-flx Hemodialysis System, a mobile, connected hemodialysis platform with integrated reverse osmosis water filtration, targeting acute care hospitals, skilled nursing facilities, chronic care clinics, and ultimately home dialysis patients.
Ownership category
akta.pro rank

Diality industry classification

Industry
Product category
Hemodialysis Systems / Dialysis Medical Devices
NAICS
Kidney Dialysis Centers (621492)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAKAA
Hemodialysis Machines & Systems
SECONDARYHLAHAKAF
Continuous Renal Replacement Therapy (CRRT) & Acute Dialysis Systems
SECONDARYHLALAFAC
Kidney & Dialysis Remote Care (CKD/ESRD monitoring, home dialysis support)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Hemodialysis equipment
  • Dialysis machines
  • Medical devices
  • Kidney care
  • Water filtration systems

Where Diality is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Diality business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Hemodialysis System Sales: Diality generates revenue through the sale of its Moda-flx Hemodialysis System to healthcare facilities including hospitals, skilled nursing facilities, and clinics. The system includes capital equipment and single-use consumables (cartridges).
  2. Consumables and Accessories: Ongoing revenue from single-use cartridges required for each dialysis treatment session, providing a recurring consumables revenue stream.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Diality product offering

Product offering

Core offering

Diality develops and manufactures the Moda-flx Hemodialysis System, a mobile, connected hemodialysis platform with integrated reverse osmosis water filtration that enables on-demand dialysate generation from tap water. The system supports a broad range of prescriptions (IHD, SLED/SLEDD, PIRRT, and 3X weekly in-center treatments) and is intended for use in acute care hospitals, post-acute care facilities, chronic care settings, and (under IDE clinical trial) home use. Revenue is generated through capital equipment sales and recurring single-use consumable cartridges to healthcare facilities.

Product overview

Diality offers a single unified product: the Moda-flx Hemodialysis System. This hemodialysis platform is designed to empower healthcare professionals to choose personalized prescriptions for kidney disease patients across various care settings. The system features fully integrated reverse osmosis water filtration, prescription flexibility supporting treatments ranging from SLED to 3X weekly in-center treatments, and a cloud-based portal for data-driven clinical decisions.

Differentiator

Problem solved

Functional benefit

Brands

  • Moda-flx: The Moda-flx Hemodialysis System is a hemodialysis platform designed to empower healthcare professionals to choose personalized hemodialysis prescriptions for patients' needs, featuring a fully integrated reverse osmosis water filtration system and an intuitive user interface designed to be easy to learn and use.

Products and services

  • Moda-flx Hemodialysis System A mobile, connected hemodialysis platform for acute care hospitals, post-acute care facilities, chronic care settings, and (under IDE) home use, featuring integrated reverse osmosis water filtration, variable dialysate and blood flow rates, a cloud-based physician data portal, and an intuitive user interface enabling sub-4-hour training.

Quantifiable outcome

  • Training time reduced to under 4 hours for new users
  • +2 more outcomes

Companies that use Diality

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Diality technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Diality partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • aQua Research InstitutecoreStrategic or Co-development Partner · 11 September 2025Diality partnered with aQua Research Institute for the PRESCRIBE Diality Home Hemodialysis Clinical Trial. The institute serves as a clinical trial site for evaluating home use of the Moda-flx system by ESRD patients on stable dialysis regimens.
  • aQua DialysiscoreStrategic or Co-development Partner · 11 September 2025aQua Dialysis in Houston, Texas is a clinical trial site partner for the PRESCRIBE Diality Home Hemodialysis Clinical Trial, treating the first patient in the home use evaluation of the Moda-flx system.
  • North America Research Institute at Ontario-Holt Dialysis CentercoreStrategic or Co-development Partner · 7 January 2025First-ever patient treatment with the Moda-flx Hemodialysis System was completed in collaboration with North America Research Institute at Ontario-Holt Dialysis Center in Ontario, California, marking the initial clinical use of the system.
  • Kidney Care PartnersminorStrategic or Co-development Partner · 14 August 2024Diality joined Kidney Care Partners, the nation's leading kidney care multi-stakeholder coalition representing patient advocates, physician organizations, health professional groups, dialysis providers, researchers, and manufacturers. Membership provides networking and advocacy opportunities in the kidney care ecosystem.
  • Paramit CorporationcoreStrategic or Co-development Partner · 28 March 2022Diality partnered with Paramit Corporation for the manufacture of its versatile hemodialysis system. The partnership was established to accelerate production and bring the system closer to market.

Scale indicators5 records

Recent moves6 records

Expansion highlights7 records

Diality competitors and assessment

Company assessment

Direct peers

  • Outset Medical: Outset Medical's Tablo Hemodialysis System is the most direct competitor to Diality's Moda-flx: a next-generation, integrated water-purification, mobile hemodialysis platform marketed across acute, in-center, and home settings. Both target the same workflow-simplification and infrastructure-reduction thesis.
  • Quanta Dialysis Technologies: Quanta's SC+ is a compact, portable hemodialysis system designed for flexibility across care settings including home use. Like Diality, Quanta targets the same underserved segments (SNF, home) with a simplified, mobile platform that challenges legacy in-center systems.
  • NxStage Medical (Fresenius Renal Therapies): NxStage pioneered home hemodialysis with the System One and was acquired by Fresenius. Its home-hemodialysis-first design philosophy and adoption among home patients overlap directly with Diality's PRESCRIBE home trial strategy.

Broad incumbents

  • Fresenius Medical Care: Fresenius is the global leader in dialysis products and services, having acquired NxStage Medical (home hemodialysis). It sells a broad portfolio of hemodialysis machines, dialyzers, and operates thousands of dialysis centers worldwide, directly competing with Diality on both device sales and downstream service economics.
  • Baxter International (Vantive): Baxter's kidney care business (recently separated as Vantive) is a long-standing incumbent in hemodialysis systems, PD systems, and dialyzers. It serves the same hospital, in-center, and home dialysis customers as Diality and has the scale, GPO contracts, and installed base to defend share aggressively.
  • Asahi Kasei Medical: Asahi Kasei is a leading global manufacturer of dialyzers and a broader renal-care portfolio. While not a direct machine-systems competitor, it is a major incumbent supplier to dialysis providers and serves overlapping nephrology customers.
  • Nipro Corporation: Nipro is a significant manufacturer of dialyzers, dialysis machines, and related renal-care products, with growing presence in the U.S. dialysis market. It competes with Diality for hospital and clinic dialysis equipment spend.

Others

  • Mar Cor Purification (Evoqua): Mar Cor is a leading provider of water purification systems for dialysis clinics — the very infrastructure Diality's integrated RO system is designed to displace. It is an adjacent/ecosystem competitor whose installed water rooms represent both an opportunity (retrofit) and a barrier (switching cost) for Diality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Diality social profiles

Digital presence

Diality compliance and trust

Trust signal

Compliance1 record

Diality financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Diality leadership team

Management profile

Number of profiles

Profiles14 records

Diality funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Diality M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diality

What does Diality do?

Diality develops and manufactures the Moda-flx Hemodialysis System, a mobile, connected hemodialysis platform with integrated reverse osmosis water filtration that enables on-demand dialysate generation from tap water. The system supports a broad range of prescriptions (IHD, SLED/SLEDD, PIRRT, and 3X weekly in-center treatments) and is intended for use in acute care hospitals, post-acute care facilities, chronic care settings, and (under IDE clinical trial) home use. Revenue is generated through capital equipment sales and recurring single-use consumable cartridges to healthcare facilities.

Is Diality a public or private company?

Diality is a private company. It is classified as venture growth investor backed and is currently operating.

When was Diality founded?

Diality was founded in 2018. It employs 101 to 250 people.

Where is Diality based?

Diality is headquartered in Irvine, United States, in the North America region.

How does Diality make money?

Two revenue lines are on record. Hemodialysis System Sales are the primary driver. The others are consumables and Accessories.

Who are Diality's main competitors?

Direct peers on record are Outset Medical, Quanta Dialysis Technologies and NxStage Medical (Fresenius Renal Therapies). Broad incumbents are Fresenius Medical Care, Baxter International (Vantive), Asahi Kasei Medical and Nipro Corporation. Mar Cor Purification (Evoqua) is listed as an others.

Does Diality have an API?

No public API is recorded for Diality.

What industry is Diality in?

Diality's product category is Hemodialysis Systems / Dialysis Medical Devices. Its primary akta.pro industry code is HLAHAKAA, Hemodialysis Machines & Systems, with a secondary code of HLAHAKAF, Continuous Renal Replacement Therapy (CRRT) & Acute Dialysis Systems. Its NAICS code is 621492 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogDiality Hosts "Expanding Choice in Hemodialysis" Expert Panel Discussion at ASN Kidney Week 2026Diality Inc. will host a panel discussion on hemodialysis at ASN Kidney Week 2026 in Denver on October 23. The panel, featuring Dr. Roberto Pecoits-Filho, Professor Bernard Canaud, and Dr. Matthew Rivara, will discuss clinical evidence for hemodiafiltration and its integration into U.S. kidney care.FinancialContent Business PageDiality Hosts "Expanding Choice in Hemodialysis" Expert Panel Discussion at ASN Kidney Week 2026Diality Inc. will host a panel discussion on hemodiafiltration at ASN Kidney Week 2026 in Denver on October 23. The panel includes experts from landmark studies like CONVINCE and MOTHER, discussing HDF integration in U.S. kidney care. The event is not a continuing education activity.Mpo-magPeter Donato Joins Diality as Chief Financial OfficerDiality Inc. has appointed Peter Donato as its new chief financial officer to support the commercialization of its Moda-flx Hemodialysis System. The appointment comes as the company continues patient enrollment in the PRESCRIBE clinical trial ahead of a planned limited market release next year. Donato brings nearly 35 years of financial leadership experience, including previous roles at Impulse Dynamics and Standard Bariatrics.Investing.comDiality names Peter Donato as chief financial officer By Investing.comDiality Inc., a medical device company based in Irvine, California developing hemodialysis systems, appointed Peter Donato as chief financial officer, with Donato bringing nearly 35 years of financial leadership experience including executive roles at multiple life science companies. The appointment comes as Diality prepares for the commercialization of its Moda-flx Hemodialysis System, which received FDA clearance in August 2024 and is targeted for limited market release in 2027. Donato previously led the IPO of Neuronetics in 2018 and served at companies including Standard Bariatrics and Assurex Health.Business Wire BlogDiality Appoints Peter Donato as Chief Financial OfficerDiality Inc., a medical device company developing the Moda-flx Hemodialysis System, has appointed Peter Donato as its new Chief Financial Officer. Donato brings nearly 35 years of financial leadership experience in the life sciences industry, including prior CFO roles at Impulse Dynamics, Zomedica, and Standard Bariatrics, as well as leading the Neuronetics IPO in 2018. The company is currently enrolling patients in its PRESCRIBE Diality Home Hemodialysis Clinical Trial and preparing for a limited market release of the Moda-flx system in 2027.OcbjDiality Treats First Patient in Home Hemodialysis StudyDiality Inc. has treated its first patient in a clinical trial evaluating the home use indication for its Moda-flx Hemodialysis System, marking a significant step toward at-home kidney disease treatment. The Irvine-based company is partnering with aQua Research Institute and aQua Dialysis for the trial while simultaneously preparing for early commercialization in professional care settings following FDA clearance. This development occurs within a growing $85 billion market, supported by recent executive appointments and strategic coalitions aimed at advancing patient policies.MassDeviceDiality enrolls first patient in hemodialysis system studyDiality has enrolled its first patient in the PRESCRIBE clinical trial for its Moda-flx home hemodialysis system, conducted in partnership with aQua Research Institute and aQua Dialysis. The trial evaluates the device's safety and efficacy for home use, building on the FDA clearance granted to the system in August 2024 for acute and chronic care settings.Business Wire BlogDiality Names Dr. Chris Springer to Board of DirectorsDiality Inc. added Dr. Chris Springer to its board of directors, bringing 30 years of commercial and strategic experience in pharmaceutical and biotech. He previously served as Chief Strategy Officer for Vifor Pharma, overseeing the $11.7B CSL acquisition. The company plans to commercialize its Moda-flx Hemodialysis System over the next 12-24 months.ZenopaDiality Gains 510(k) Approval for Moda-fix SystemDiality received 510(k) approval from the US FDA for its Moda-fix haemodialysis system, a device designed to treat acute and chronic renal failure with variable flow rate capabilities. This regulatory clearance allows the Irvine-based company to proceed with commercial sales of the integrated treatment platform. The approval marks a significant milestone in Diality's mission to improve kidney disease care.FierceBiotechDiality secures FDA clearance for hemodialysis systemDiality, an Irvine-based medical device company, secured U.S. Food and Drug Administration 510(k) clearance for its Moda-flx hemodialysis system used for acute and chronic renal failure. This regulatory approval is a prerequisite that allows the company to market the new product commercially at least 90 days before its official launch.